May 4 - 6, 2017
Grand Hyatt São Paulo
São Paulo, Brazil
Abstract submission deadline: Monday, February 20
Advance registration deadline: Monday, March 13
May 4-6, 2017Grand Hyatt São PauloSão Paulo, Brazil
Conference CochairsCarlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA (AACR)Carlos Gil M. Ferreira, D’or Institute for Research and Education, Rio de Janeiro, Brazil (LACOG)
Program CommitteeDyeison Antonow, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, BrazilOscar G. Arrieta, Instituto Nacional de Cancerología, Mexico City, MexicoCarlos H. Barrios, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, BrazilCristina B. Bonorino, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, BrazilAndres F. Cardona, Fundación Santa Fe de Bogotá, Bogotá, ColombiaEmmanuel Dias-Neto, A.C. Camargo Cancer Center, São Paulo, SP, BrazilKeith T. Flaherty, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USAPaulo M. Hoff, Centro de Oncologia, São Paulo, SP, BrazilElizabeth M. Jaffee, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USAPatricio Manque, Universidad Mayor, Santiago, ChileAri M. Melnick, Weill Cornell Medical College, New York, New York, USALillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, CanadaDavid B. Solit, Memorial Sloan Kettering Cancer Center, New York, New York, USALouis M. Staudt, National Cancer Institute, Bethesda, Maryland, USAGregory L. Verdine, Harvard University, Cambridge, Massachusetts, USA
The AACR International Conference on Translational Cancer Medicine, being held in cooperation with the
Latin American Cooperative Oncology Group (LACOG), will appeal to a broad spectrum of cancer researchers—from laboratory scientists and translational cancer researchers to clinical researchers and clinical oncologists in all disciplines of the cancer field—by presenting an overview of state-of-the-art translational cancer research and exploring the latest discoveries in targeted therapies and drug resistance, cancer immunology and immunotherapy, preclinical models, tumor heterogeneity and the tumor microenvironment, drug discovery, and clinical trials among other key areas in the field. This meeting, which will be historic in its impact, will also have sessions that focus on the most common cancers in Latin America.
The AACR and LACOG Co-chairpersons and the members of the Program Committee have developed what should be a landmark conference that bridges basic and clinical research and thus fosters translational cancer research in Latin America. Throughout the discussions about the program, the need to bridge the gap between basic research and clinical care has been a primary objective for this program. Leading researchers from North, Central, and South America have committed to participate and present their research at this event. This conference will be historic in its impact and will attract 300-400 attendees—most of whom will be working in Latin America or have collaborations/connections to research being conducted in the region. The leadership of both AACR and LACOG recognize the overall long-term value in providing service to its constituencies by collaborating on the development of this conference and expect that this will be the "must attend" translational cancer research program in Latin America.
Top of page